Regenerative Medical Technologies Group

What Regenerative Medical Technologies Group does

Regenerative Medical Technologies Group (RMTG) is a publicly traded (OTC: RMTG) regenerative medicine platform that operates a vertically integrated ecosystem spanning physician training, biologics manufacturing, clinic operations, and AI-powered clinical decision support. Through its ISSCA (International Society for Stem Cell Application) alliance, the company delivers certified physician training across a network spanning 30+ countries, with 26 affiliated clinics in 21 countries. Its Cellgenic subsidiary operates a first-of-its-kind xeno-free biologics manufacturing facility in Cancún, Mexico, producing six product lines — exosomes, mesenchymal stem cells (MSCs), NK cells, allogeneic fibroblasts, sterile diluents, and lyophilized exosomes — under COFEPRIS-guided frameworks and distributed via an Authorized Distributor Program. The company also sells stem cell processing equipment and turnkey lab solutions, and provides patient treatments covering musculoskeletal, autoimmune, aesthetic, and anti-aging conditions.

The company generates revenue across five streams: physician training and certification (professional services), equipment and supplies sales (hardware), patient procedures at affiliated clinics (professional services), Cellgenic biologics manufacturing and distribution (hardware), and turnkey stem cell processing center solutions (professional services). Q1 2025 reported sales of $1.35M with $134K operational profit, representing 67% YoY growth, though 100% of revenue is derived from international emerging markets (Brazil and Pakistan) per the 2025 Annual Report. The product surface expanded materially in 2026 with the launch of the ISSCA AI Clinical Intelligence Platform in June 2026 — a next-generation AI system leveraging 30+ years of patient history data — and the full-scale Cellgenic manufacturing launch in March 2026. The company carries an accumulated deficit of $75.4M and working capital deficit of $35.6M as of December 31, 2025, a going concern warning from auditors, and has filed late SEC reports in 2026, all of which materially constrain the financial trajectory despite positive operating momentum.

Name

Regenerative Medical Technologies Group

Legal name

Regenerative Medical Technology Group Inc.

Website

https://regenmedtechgroup.com

Company type

Public

Founded year

2024

Operating status

Operating

Headcount range

11–50 employees

Short description

Regenerative Medical Technologies Group is a publicly traded regenerative medicine platform operating an integrated ecosystem of physician training (ISSCA), xeno-free biologics manufacturing (Cellgenic), affiliated clinics in 21 countries, and the newly launched ISSCA AI clinical intelligence platform, serving regenerative medicine physicians and patients internationally.

Ownership category

akta.pro rank

Product category

Regenerative Medicine

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Medical Equipment and Supplies Manufacturing (3391), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Stem Cell–Based Regenerative Therapies (HLAAAGAA)

akta.pro secondary industries

Cell Therapy CDMO (HLAGABAD), Cell Therapy CDMO (Autologous/Allogeneic Manufacturing) (HLAGAGAA)

Keywords

• Regenerative medicine
• Stem cell therapy
• Biologics manufacturing
• Physician training
• Clinical intelligence platform

Headquarters

HQ city

Boca Raton

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Physician Training and Certification: RMTG offers specialized and certified training courses to physicians through ISSCA alliance, ensuring they are equipped with the latest knowledge and skills in stem cell therapies. Training is a key entry point for the physician network.
2. Equipment and Supplies Sales: Manufacturing and sale of state-of-the-art technology, supplies, and equipment related to stem cell applications, catering to the needs of medical professionals in the field.
3. Patient Procedures: Revenue from regenerative medicine treatments provided at company-owned and affiliated clinics. Treatments cover musculoskeletal disorders, autoimmune diseases, aesthetics, and anti-aging.
4. Biologics Manufacturing: Cellgenic subsidiary generates revenue from manufacturing and distributing biologic products including exosomes, MSCs, NK cells, and allogeneic fibroblasts to international markets through authorized distributor network.
5. Turnkey Stem Cell Processing Center Solutions: Comprehensive turnkey solutions for the installation and management of stem cell processing centers, providing a one-stop solution for practitioners entering the field.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Core offering

RMTG operates an integrated regenerative medicine platform that develops and distributes stem-cell-based clinical products, biologic products, and lab/clinic equipment, while also delivering physician training, certification, patient clinic services, and turnkey stem cell processing center solutions. Through its Cellgenic subsidiary it manufactures xeno-free biologics (exosomes, MSCs, NK cells, allogeneic fibroblasts) and through ISSCA it provides global physician education and certification across 30+ countries.

Product overview

Regenerative Medical Technologies Group operates as an integrated regenerative medicine platform with multiple subsidiaries and product lines. The core ecosystem consists of the ISSCA AI™ Clinical Intelligence Platform (AI-powered clinical decision support), the Global Stem Cells Group subsidiary for research and training, the Cellgenic biologics manufacturing subsidiary (producing six product lines including exosomes, MSCs, NK cells, and allogeneic fibroblasts from its xeno-free Cancún facility), and the ISSCA education division providing physician certification. Additional brands include Cellular Hope Institute clinics, Stem Cell Center Network (20+ member clinics globally), VitaNovas, Gcell, and AdiMarket. The company offers services spanning physician training, equipment manufacturing, clinical protocol R&D, patient clinics, and turnkey processing center solutions. The technology-enabled ecosystem connects clinical services, education, biologics manufacturing, and AI infrastructure across 30+ countries.

Differentiator

Problem solved

Functional benefit

Brands

• Cellgenic: Advanced xeno-free biologics manufacturing subsidiary producing exosomes, mesenchymal stem cells (MSCs), NK cells, and allogeneic fibroblasts at its facility in Cancún, Mexico.
• ISSCA AI™ Clinical Intelligence Platform
• Global Stem Cells Group
• ISSCA (International Society for Stem Cell Application)
• Cellular Hope Institute
• Stem Cell Center

Products and services

• ISSCA AI Clinical Intelligence Platform An AI-powered clinical decision support platform that assists physicians in interpreting clinical data, organizing treatment workflows, and managing data complexity across regenerative medicine practices.
• Cellgenic Xeno-Free Biologics Product Lines Six biologic product lines manufactured at a xeno-free facility in Cancún, Mexico: exosomes, mesenchymal stem cells (MSCs), NK cells, allogeneic fibroblasts, sterile diluents, and lyophilized exosomes, distributed to authorized medical professionals internationally under COFEPRIS frameworks.
• Certified Training Courses for Physicians Specialized and certified training programs delivered through ISSCA that equip physicians with the latest knowledge and skills in stem cell therapies and regenerative medicine.
• Manufacturing & Sales of Equipment and Supplies Production and sale of state-of-the-art lab and clinic technology, supplies, and equipment related to stem cell applications for medical professionals.
• Regenerative Medicine Clinics for Patients Provision of standardized regenerative medicine treatments covering musculoskeletal disorders, autoimmune diseases, aesthetics, and anti-aging at company-owned and affiliated clinics globally.
• Turnkey Stem Cell Processing Center Solutions Comprehensive turnkey solutions for the installation and management of stem cell processing centers, providing a one-stop solution for practitioners entering the regenerative medicine field.
• Cellular Hope Institute Regenerative medicine clinic providing standardized treatments for patients, part of RMTG's global clinic network.
• Stem Cell Center Network Global network of 26 member clinics in 21 countries providing regenerative medicine treatments.

Quantifiable outcome

• 67% year-over-year revenue growth in Q1 2025
• +2 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature3 records

Partnerships

Three partnerships are on record, tiered core and minor.

• StembiocoreStrategic or Co-development Partner · 1 January 2024Global Stem Cells Group announced collaboration with Stembio following the World Regenerative Medicine Congress in Istanbul. Both companies specialize in regenerative medicine aimed at changing, repairing, or regenerating human or animal cells, tissues, or organs to restore damaged tissues or organs due to disease, trauma, or congenital issues.
• International Society for Stem Cell Application (ISSCA)coreStrategic or Co-development PartnerFounding partner of ISSCA alliance initiative. RMTG operates ISSCA education division which provides comprehensive physician training and certification programs in stem cell applications. ISSCA represents the company's core education and training platform.
• The Doney Law FirmminorImplementation/ SI/ Consulting PartnerTrusted legal advisor located at 3651 Lindell Road, Suite D121, Las Vegas, NV 89103

Scale indicators10 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Capricor Therapeutics: Clinical-stage cell therapy company developing allogeneic cardiosphere-derived cells. Comparable as a regenerative medicine peer operating in the cell-based therapeutics space adjacent to MSC/NK cell products.
• Vericel: Commercial-stage cell therapy company (MACI, Epicel) selling autologous and allogeneic regenerative products into orthopedic and burn clinics. Comparable as a regenerative medicine company combining cell manufacturing with clinic-channel sales.
• Cellect Biotechnology: Stem cell selection and manufacturing technology company. Comparable as a stem cell processing technology and biologics manufacturing peer adjacent to RMTG's Cellgenic platform.
• Celltex Therapeutics: US-based adult stem cell banking and therapy company with significant operations in Mexico. Highly comparable given overlapping geographic focus and stem cell therapy offerings that mirror RMTG's Mexico-anchored operations.
• BrainStorm Cell Therapeutics: Autologous cell therapy company developing MSC-based products for neurodegenerative diseases. Comparable as a stem cell therapy peer with a similar MSC-centric product approach.
• Pluristem Therapeutics: Placental-derived cell therapy company developing allogeneic cell products. Directly comparable to Cellgenic's allogeneic fibroblast and MSC manufacturing focus.
• Organogenesis Holdings: Commercial regenerative medicine company selling living cell-based wound care and surgical biologics. Comparable as a vertically integrated regenerative medicine products business with clinic-channel distribution.
• Mesoblast: Commercial-stage cell therapy company developing mesenchymal lineage cell products. Most directly comparable to RMTG's MSC-based biologics platform and Cellgenic's MSC manufacturing line.

Broad incumbents

• Catalent: Major CDMO with biologics and cell therapy manufacturing capabilities. Comparable as a broad incumbent providing biologics manufacturing services competitive with Cellgenic's specialty cell therapy manufacturing.
• Lonza Group: Global contract development and manufacturing organization (CDMO) with a large cell and gene therapy services franchise. Comparable as a much larger incumbent offering biologics manufacturing services that overlap with Cellgenic's offering.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/highlights
• LinkedInlinkedin.com/company/regenmedtechgroup

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Regenerative Medical Technologies Group